SMT19969
SMT19969/C002
Phase 2 small_molecule completed
Quick answer
SMT19969 for Clostridium Difficile Infection is a Phase 2 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Summit Therapeutics
- Indication
- Clostridium Difficile Infection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed